exogenous recombinant rat il 6  (R&D Systems)

Journal: PLOS One

Article Title: Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis

doi: 10.1371/journal.pone.0341049

Figure Lengend Snippet: (A) Inhibition of IL-17 bioactivity as secreted by human TH17 cells and assayed by a reporter cell assay. Dotted lines represent positive and negative assay controls. 1 representative of 7 experiments with different donors is shown. The error bars represent the SEM. (B, C) Evaluation of DC-806 in rat CIA. Rats were randomized on Day 11 and dosed as indicated. Daily measurements of ankle thickness (B) and terminal measurement of footpad weights (C) were used as efficacy readouts. (D) Preclinical evaluation of DC-806 serum levels. PK sampling for exposure determination was performed on Days 11, 16, at 1 and 12 hours post dose. The dotted lines represent the uncorrected IC 50 for rat IL-17AA and rat IL-17AF as listed in . The dashed line represents the LLQ of the quantification assay. All error bars represent the SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Abbreviations : anti-F, anti-IL-17F; BID, twice daily; CIA, collagen-induced arthritis; Dex, dexamethasone; IC 50 , half-maximal inhibitory concentration; IL-17, interleukin-17; LLQ, lower limit of quantification; PK, pharmacokinetic; QD, once daily; SEM, standard error of mean; TH17, T-helper 17.

Article Snippet: To determine cellular potency, recombinant human (h)IL-17AA (Genscript cat# Z03228), hIL-17AF (R&D cat# 5837-IL-010), hIL-17FF (R&D Systems 1335-IL), rat IL-17AA (R&D systems 8410-IL-025), and rat IL-17AF (R&D systems 9340-IL-025) were used for in vitro stimulation at the concentrations listed in .

Techniques: Inhibition, Sampling, Concentration Assay

Journal: PLOS One

Article Title: Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis

doi: 10.1371/journal.pone.0341049

Figure Lengend Snippet: Graph detailing the group mean ± SD DC-806 plasma concentration by 200 mg BID (green circle) and 800 mg BID (blue diamond) groups on a semilogarithmic scale through Study Day 29. PK in psoriasis patients was comparable to healthy volunteer PK, with consistent trough levels over 28 days after achieving steady state around Day 3. The dotted line represents IC 50 for recombinant human IL-17AA, as obtained using HEK-blue IL-17 cell-based assay . PK Concentration Analysis Set. Abbreviations : BID, twice daily; HEK: human embryonic kidney; IC 50 , half-maximal inhibitory concentration; IL-17, interleukin-17; PK, pharmacokinetic; SD, standard deviation.

Article Snippet: To determine cellular potency, recombinant human (h)IL-17AA (Genscript cat# Z03228), hIL-17AF (R&D cat# 5837-IL-010), hIL-17FF (R&D Systems 1335-IL), rat IL-17AA (R&D systems 8410-IL-025), and rat IL-17AF (R&D systems 9340-IL-025) were used for in vitro stimulation at the concentrations listed in .

Techniques: Clinical Proteomics, Concentration Assay, Recombinant, Cell Based Assay, Standard Deviation

Journal: PLOS One

Article Title: Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis

doi: 10.1371/journal.pone.0341049

Figure Lengend Snippet: (A–C) DC-806 demonstrated biological effects as evidenced by dose-dependent responses of biomarkers of interest compared to placebo. Blue diamonds represent the 800 mg BID group; Green circles represent the 200 mg BID group; Black triangles represent the placebo group. (A) Change in mean ± SEM serum IL-17AA levels from time of first dose through 28 days post first dose. The dotted line represents low limit of quantification of the assay. (B) Change in mean ± SEM serum BD-2 levels from time of first dose through 28 days thereafter. *Except on Day 28 when n = 10; **Except on Day 28 when n = 9. (C) Change in mean ± SEM plasma IL-19 levels from time of first dose through 28 days post first dose. The dotted line represents normalization value of 21 pg/mL. PD Biomarker Analysis Set. Abbreviations: BD-2, beta defensin-2; BID, twice daily; BL, baseline; IL-17, interleukin-17; PASI, psoriasis area and severity index; PD, pharmacodynamic; SEM, standard error of mean.

Article Snippet: To determine cellular potency, recombinant human (h)IL-17AA (Genscript cat# Z03228), hIL-17AF (R&D cat# 5837-IL-010), hIL-17FF (R&D Systems 1335-IL), rat IL-17AA (R&D systems 8410-IL-025), and rat IL-17AF (R&D systems 9340-IL-025) were used for in vitro stimulation at the concentrations listed in .

Techniques: Clinical Proteomics, Biomarker Discovery

Journal: PLOS One

Article Title: Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis

doi: 10.1371/journal.pone.0341049

Figure Lengend Snippet: (A) Inhibition of IL-17 bioactivity as secreted by human TH17 cells and assayed by a reporter cell assay. Dotted lines represent positive and negative assay controls. 1 representative of 7 experiments with different donors is shown. The error bars represent the SEM. (B, C) Evaluation of DC-806 in rat CIA. Rats were randomized on Day 11 and dosed as indicated. Daily measurements of ankle thickness (B) and terminal measurement of footpad weights (C) were used as efficacy readouts. (D) Preclinical evaluation of DC-806 serum levels. PK sampling for exposure determination was performed on Days 11, 16, at 1 and 12 hours post dose. The dotted lines represent the uncorrected IC 50 for rat IL-17AA and rat IL-17AF as listed in . The dashed line represents the LLQ of the quantification assay. All error bars represent the SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Abbreviations : anti-F, anti-IL-17F; BID, twice daily; CIA, collagen-induced arthritis; Dex, dexamethasone; IC 50 , half-maximal inhibitory concentration; IL-17, interleukin-17; LLQ, lower limit of quantification; PK, pharmacokinetic; QD, once daily; SEM, standard error of mean; TH17, T-helper 17.

Article Snippet: To determine cellular potency, recombinant human (h)IL-17AA (Genscript cat# Z03228), hIL-17AF (R&D cat# 5837-IL-010), hIL-17FF (R&D Systems 1335-IL), rat IL-17AA (R&D systems 8410-IL-025), and rat IL-17AF (R&D systems 9340-IL-025) were used for in vitro stimulation at the concentrations listed in .

Techniques: Inhibition, Sampling, Concentration Assay

Journal: Journal of Nanobiotechnology

Article Title: Cerium-doped prussian blue nanozymes for bone regeneration and osteoprotection by Lhx2 in sutural distraction osteogenesis through multi-omics analysis

doi: 10.1186/s12951-025-03931-9

Figure Lengend Snippet: Systematical observation and analysis of bone remodeling and regeneration within the mid-palatal suture expansion by histological and immunohistochemical staining. ( A ) HE and Masson’s trichrome staining. ( B ) TRAP staining and IHC staining of OCN, CD31, RANKL and OPG expression. Black arrows indicate osteoclasts in mid-palatal suture. ( C ) The number of osteoclasts per square millimeter was quantified through TRAP staining. H-Score of ( D ) OCN, ( E ) CD31, ( F ) RANKL and ( G ) OPG. ( H ) The relative value of H-Score of RANKL to OPG (* p < 0.05, ** p < 0.01, *** p < 0.001 and ns means no significance). H -Score: histochemistry score

Article Snippet: Rat M-CSF recombinant protein was purchased from PeproTech ® , USA and Rat RANKL recombinant protein was purchased from R&D Systems, USA.

Techniques: Immunohistochemical staining, Staining, Immunohistochemistry, Expressing

Journal: Journal of Nanobiotechnology

Article Title: Cerium-doped prussian blue nanozymes for bone regeneration and osteoprotection by Lhx2 in sutural distraction osteogenesis through multi-omics analysis

doi: 10.1186/s12951-025-03931-9

Figure Lengend Snippet: Systematical observation and analysis of bone remodeling and regeneration within the mid-palatal suture excessive expansion by histological and immunohistochemical staining. ( A ) HE and Masson’s trichrome staining. (B ) TRAP staining and IHC staining of OCN, CD31, RANKL and OPG expression. Black arrows indicate osteoclasts in mid-palatal suture. ( C ) The number of osteoclasts per square millimeter was quantified through TRAP staining. H-Score of ( D ) OCN, ( E ) CD31, ( F ) RANKL and (G ) OPG. ( H ) The relative value of H-Score of RANKL to OPG (* p < 0.05, ** p < 0.01, *** p < 0.001 and ns means no significance). H-Score: histochemistry score

Article Snippet: Rat M-CSF recombinant protein was purchased from PeproTech ® , USA and Rat RANKL recombinant protein was purchased from R&D Systems, USA.

Techniques: Immunohistochemical staining, Staining, Immunohistochemistry, Expressing

Journal: Microorganisms

Article Title: Heat-Inactivated Selenium Nanoparticle-Enriched Lactobacillus Enhance Mucosal IgA Responses and Systemic Responses of Clostridium perfringens Multi-Epitope Vaccine Correlated with TGF-β and NF-κB Pathways in Mice

doi: 10.3390/microorganisms14010180

Figure Lengend Snippet: The cytokines induced by HiSeL in mice. The levels of TGF-β and IL-5 were measured at 28 dpi in the serum using ELISA, and the mRNA expression levels of IFN-γ, IL-12, TNF-α, IL-10, IL-1β, and IL-4 in the spleen were measured by RT-qPCR. The data are presented as mean ± SD (* p < 0.05, ** p < 0.01, **** p < 0.0001).

Article Snippet: TGF-β1 and IL-5 in serum were tested by ELISA kits (Boster Bioengineering, Wuhan, China) following the manufacturer’s protocol.

Techniques: Enzyme-linked Immunosorbent Assay, Expressing, Quantitative RT-PCR

Journal: bioRxiv

Article Title: High-resolution promoter interaction analysis implicates genes involved in the activation of Type 3 Innate Lymphoid Cells in autoimmune disease risk

doi: 10.1101/2022.10.19.512842

Figure Lengend Snippet: A. Interaction profile of the human CLN3 promoter alongside the tracks of TF binding, blood eQTLs, CD GWAS and SuSiE posterior probabilities of inclusion. Dark blue and light blue bands, respectively, highlight the locations of annotated CLN3 promoters and promoter-proximal regions (+/− 5 restriction fragments) considered by multiCOGS in addition to PIRs. Red band highlights the ILC3-specific PIR containing CD-associated SNPs with high posterior probability of inclusion. Orange and purple arcs, respectively, depict significant interactions (CHiCAGO score > 5) in ILC3s at 5kb and single-fragment resolution. B. Up- and downregulation of Cln3 and Apobr upon TL1A stimulation in mouse primary ILC3s (RNA-seq data from Ref. ) and upon IL-23/IL-1β stimulation in CLN3-targeted CRISPRi and CRISPRa MNK-3 cells (RNA-seq data from this study). C. Differential expression of genes in IL-23/IL-1β-stimulated Cln3 -CRISPRa MNK-3 cells relative to scrambled gRNA controls. Red dots - differentially expressed genes (stimulated Cln3- CRISPRa DEGs, DESeq2 adjusted p-value < 0.05), with other genes shown as green dots. D. Network-style representation of GO term enrichment analysis of stimulated Cln3- CRISPRa DEGs. E. Changes in the expression of stimulated Cln3- CRISPRa DEGs (dots) upon either IL-23/IL-1β or TL1A stimulation of unperturbed MNK-3 cells (data from Ref. ). F. Evidence that Cln3 overexpression decreases inflammatory cytokine secretion. MNK-3 cells were electroporated with GFP mRNA (black) or Cln3-myc mRNA (red), then cultured either unstimulated (top row) or stimulated with IL-1β and IL-23 (bottom row) for 24 hr. Cytokine concentrations (IL-17, IL-22, GM-CSF) in culture supernatants were quantified by ELISA. Each point represents an individual biological replicate (n=10 per condition). The data shown are from one representative experiment of three independent experiments performed. Dotted line indicates the lower limit of quantification for each assay. Statistical significance was assessed using an unpaired Welch’s t-test. p<0.01 (**), p<0.001 (***), p<0.0001 (****).

Article Snippet: Transfected cells were cultured for an additional 24 hr in the presence or absence of recombinant mouse 10 ng/mL IL-1β and 10 ng/mL IL-23 (R&D Systems).

Techniques: Binding Assay, RNA Sequencing, Quantitative Proteomics, Expressing, Over Expression, Cell Culture, Enzyme-linked Immunosorbent Assay